中文摘要：

目的：研究视黄醇结合蛋白4（retinol binding protein 4,RPB4）基因rs3758539G-803A和rs10882283T-179G多态性对中国人群2型糖尿病患者使用罗格列酮疗效的影响。方法：使用PCR-RFLP方法对472名2型糖尿病患者和198名健康对照者进行RPB4基因G-803A和T-179G多态性位点的基因分型。随机选择42名携带不同RBP4基因型的2型糖尿病患者给予12周每天4 mg的罗格列酮口服治疗。检测用药前后空腹血糖（fasting plasma glucose,FPG）、餐后血糖（postprandial plasma glucose,PPG）、空腹胰岛素（fastingserum insulin,FINS）、餐后胰岛素（postprandial serum insulin,PINS）、糖化血红蛋白（glycated hemoglobin,HbAlc）、甘油三酯（triglyceride,TG）、低密度脂蛋白胆固醇（low-density lipoprotein-cholesterol,LDL-c））和高度脂蛋白胆固醇（high-density lipoprotein-cholesterol,HDL-c）等指标。结果：携带RBP4 G-803A GG基因型的患者其TG和LCL-c水平显著低于GA＋AA基因型患者。携带T-179G TT基因型的患者其腰臀比、FPG和FINS值显著低于TG＋GG基因型患者。携带RBP4 G-803A GG基因型的患者服用罗格列酮后FPG和FINS下降值优于GA＋AA基因型患者。携带T-179G TG＋GG基因型的患者服用罗格列酮后的HbAlc下降值优于TT基因型患者。结论：RBP4 G-803A和T-179G基因多态性与2型糖尿病相关且影响罗格列酮的疗效。

英文摘要：

Objective To explore the association between rs3758539G-803A and rs10882283T-179G polymorphism of retinol binding protein 4（RBP4） and rosiglitazone response in Chinese type 2 diabetes mellitus（T2DM） patients.Methods A total of 472 Chinese T2DM patients and 198 healthy subjects were enrolled to identify G-803A and T-179G genotypes using a polymerase chain reaction-restriction fragment length polymorphism（PCR-RFLP） assay.Forty-two T2DM patients with different G-803A or T-179G genotypes were selected to undergo a 12-week rosiglitazone treatment（4 mg/d）.Serum fasting plasma glucose（FPG）,postprandial plasma glucose（PPG）,fasting serum insulin（FINS）,glycated hemoglobin（HbAlc）,postprandial serum insulin（PINS）,triglyceride（TG）,low-density lipoprotein-cholesterol（LDL-c）,and high-density lipoprotein-cholesterol（HDL-c） were determined before and after the rosiglitazone treatment.Results T2DM patients with RBP4 G-803A GG genotype showed lower TG and LDL-c concentrations compared with that in the GA＋AA genotype subjects.T2DM patients with RBP4 T-179G TT genotype showed lower waist-to-hip ratio（WHR）,FPG and FINS values compared with that in the TG＋GG genotype individuals.Patients with GG genotype of RBP4 G-803A had an enhanced rosiglitazone efficacy on FPG and FINS compared with that in the GA＋AA genotype group.Patients with RBP4 T-179G TG＋GG genotype showed an enhanced rosiglitazone efficacy on HbAlc level compared with that in the TT genotype group.Conclusion RBP4 G-803A and T-179G polymorphism might be associated with the development of T2DM and affect the therapeutic efficacy of rosignitazone in Chinese T2DM patients.